Compositions and methods of modulating HIF-2A to improve muscle generation and repair
Compositions and methods for modulating HIF-2α to meditate of hypoxia signaling in satellite cells and applications thereof for improving skeletal muscle generation and repair are provided. For example, methods of enhancing, increasing, accelerating or/and otherwise improving skeletal muscle generation or regeneration in a subject in need thereof are disclosed. In some embodiments, the methods include administering the subject an effective amount of HIF-2α inhibitor. The HIF-2α inhibitor can be effective to, for example, increase muscle satellite cell proliferation, differentiation, or a combination thereof in a subject. Composition and methods for improving respiration, and reducing or preventing the development or progression of fibrosis are also provided. The disclosed compositions and methods are particularly useful for treating muscular dystrophies, myopathies, and other muscle-related diseases and disorders.
1. A method of enhancing, increasing, accelerating or/and otherwise improving skeletal muscle generation or regeneration in a subject in need thereof comprising administering the subject an effective amount of HIF-2α inhibitor.
2. The method of claim 1 , wherein the HIF-2α inhibitor is effective to increase muscle satellite cell proliferation, differentiation, or a combination thereof in a subject.
3. The method of claim 1 , where the HIF-2α inhibitor is effective to increase or accelerate differentiation of satellite cells into myoblasts in the subject.
4. The method of claim 1 , wherein the HIF-2α inhibitor is a small molecule or a functional nucleic acid.
5. The method of claim 4 , wherein the HIF-2α inhibitor is the small molecule PT2385, PT2977, PT-2399, or a derivative, stereoisomer, or pharmaceutically acceptable salt thereof.
6. The method of claim 4 , wherein the HIF-2α inhibitor is a functional nucleic acid selected from the group consisting of antisense molecules, siRNA, miRNA, aptamers, ribozymes, triplex forming molecules, RNAi, and external guide sequences that targets the HIF-2α gene or a gene product thereof.
7. The method of claim 1 , wherein the HIF-2α inhibitor is targeted to skeletal muscle.
8. The method of claim 1 , wherein the HIF-2α inhibitor is administered to the subject by an oral, parenteral, transdermal, or transmucosal administration.
9. The method of claim 1 , wherein the HIF-2α inhibitor is administered to the subject locally or systemically.
10. The method of claim 1 wherein the subject has a skeletal muscle injury.
11. The method of claim 1 wherein the subject has a skeletal muscle disease or disorder.
12. The method of claim 1 , wherein the method increases myofiber number, length, density, cross sectional area, or a combination thereof, increases muscle strength or volume, or any combination thereof in the subject.
13. The method of claim 1 , wherein the subject has a muscular dystrophy or myopathogenic disorder, fibrosis, poor respiration, or a combination thereof.
14. The method of claim 13 , wherein the muscular dystrophy or myopathic disorder is one or more of a dystrophin-glycoprotein complex (DGC)-related dystrophy, a congenital muscular dystrophy, a muscle-eye-brain disease, a facioscapulohumeral dystrophy, a limb-girdle muscular dystrophy, ocular muscular dystrophy, and oculpharyngeal muscular dystrophy, a myotonic dystrophy an oculopharyngeal muscular dystrophy, a congenital myopathy, a toxic myopathy, an inflammatory myopathy, an endocrine or metabolic myopathy, a vitamin D deficiency, a mitochondrial myopathy, glycogenoses, a lipid storage myopathy, a myotonic disease, and periodic paralyses.
15. The method of claim 13 , wherein the muscular dystrophy or myopathic disorder is Bethlem myopathy, Bethlem congenital muscular dystrophy (CMD), Duchenne Muscular Dystrophy, Becker dystrophy, Fukuyama CMD, Ullrich CMD, Walker-Warburg syndrome, Emery-Dreifuss Muscular Dystrophy, a limb-girdle muscular dystrophy 2 (2A-2L), myotonic dystrophy type 1, myotonic dystrophy type 2, rigid spine syndrome, or myasthenia gravis.
16. A method of increasing skeletal muscle generation or regeneration comprising administering to a subject with a skeletal muscle injury, disease, or disorder an effective amount of a small molecule HIF-2α inhibitor to increase skeletal muscle generation or regeneration.
17. The method of claim 16 , wherein the small molecule is PT2385, PT2977, PT-2399, or pharmaceutically acceptable salt thereof.
18. The method of claim 17 , wherein the small molecule is administered orally to the subject.
19. The method of claim 17 , wherein the small molecule is administered to a muscle in need of skeletal muscle generation or regeneration.
20. The method of claim 18 , wherein the disease a muscular dystrophy.